Medical Developments International : MVP FY22 Half Year Investor Presentation

onlyMVP FY22 Half Year Results & Investor Presentation

Gordon Naylor - Chair Brent MacGregor - CEO

use25 February 2022 10am AEDT

ersonalInvestors can register in advance

for this presentation via the following link: https://us02web.zoom.us/meetin g/register/tZMpceqpqTsvH9WuY m0evrIBU3ydUplXsxhN

onlyuse ersonalDisclaimer

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. pricing and product initiatives of competitors;
2. legislative and regulatory developments and economic conditions;
3. delay or inability in obtaining regulatory approvals or bringing products to market;
4. fluctuations in currency exchange rates and general financial market conditions;
5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6. increased government pricing pressures;
7. interruptions in production;
8. loss or inability to obtain adequate protection for intellectual property rights;
9. litigation;
10. loss of key executives or other employees; and
11. adverse publicity and news coverage.

There can be no assurance that any existing or future regulatory filings will satisfy any health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Medical Development International Limited is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Any statements regarding earnings is not a profit forecast and should not be interpreted to mean that Medical Developments International's earnings for this year or any subsequent period will necessarily match or exceed the historical published earnings of Medical Developments International. Medical Developments International Limited, its directors, officers and employees do not accept any liability whatsoever for any damage or loss caused by anything contained in this document.

For marketed products discussed in this presentation, please see full prescribing information on our website at www.medicaldev.com

All mentioned trademarks are legally protected.

Half Year Highlights

	FY22 H1 Statutory Financials	$m
only
Gross Revenue	9.9
Gross Margin	5.6
EBIT	(9.4)
Net Profit/(Loss) After Tax	(7.4)
use
Cash on hand	28.3
Key Sales	Growth on Prior
		Period
	Penthrox Australia	131%
ersonal	163%
	Penthrox EU
	Australian Respiratory	56%
	US Respiratory	56%
3

Renewed focus delivering across key markets

• Strong rebound for Penthrox in Australia continuing on momentum from H2 FY21
• Penthrox EU - first full 6 months under MVP control returning encouraging growth - France the key driver
• Australian Respiratory rebounding from COVID-19
• US Respiratory - a strong performance - significant growth potential remains

Gross Revenue Bridge

onlyuse ersonal4

Gross sales revenue grew 55%

• Non-recurringcontract income in FY21 H1
• Following handback from previous distributor, Australian Penthrox sales have returned to pre- pandemic levels despite restrictions in NSW and
  VIC
• EU Penthrox sales have been robust despite restricted hospital access in France
• Australian respiratory sales are benefiting from focused resourcing
• Focus on Walgreens and Walmart has driven strong sales growth

EBIT Bridge

onlyuse ersonal5

EBIT comparable when excluding non-operating impacts

• FY21 H1 contract income is non-recurring
• JobKeeper subsidies ended in March 21
• Human capital represents investment in personnel and share based payments
• Impairments relate to the FY22 H1 Veterinary goodwill write off and CSIRO Project costs